Aphria Inc (NYSE:APHA) Speaks Out On Althea’s Manufacturing License

Aphria Inc (NYSE:APHA) is quite impressed by the recent success of its partner Althea. This business partner is based in Australian and has been struggling to obtain a manufacturing license.

About the license

 Aphria has confirmed today that Althea will be free to conduct its business operations. This partner has been looking forward to obtaining proper licensing so that it can freely engage in its manufacturing activities.

Vic Neufeld, who is the CEO of Aphria, has been closely following the activities of the partners. He is impressed by the landmark step and believes that the Althea shareholders can look forward to a brighter future. One of the things they might witness is the establishment of a top-notch medicinal cannabis operation and even more.

Fegan’s thoughts

The CEO of Althea Josh Fegan said that this was a significant step forward for their business. It provided them with authority to engage in the manufacture of cannabis extracts and tinctures. According to him, they are ready to channel resources to produce products following the stipulations of the permit.

Fegan says that they are quite pleased about their success. He also spoke about their existing license for Medicinal Cannabis. According to him, these are very important documents that will see them revamp their production activities.

Fegan has severally congratulated his team for their contributions towards the increased momentum in growth. He has termed the Manufacture License as a great addition that will see them become very competitive.

He also delved deeper to speak about the patients that have already been approved for the company’s medicinal cannabis products. According to him, the number has already surpassed the already set 100 patient milestone. About 127 patients have been approved so far.

The other way to look at the massive success of this business guru is the referrals being made. Reports indicate that many doctors have been prescribing this company’s wide-ranging products to their patients.

Initially, the number prescribing these products stood at 42.Thta number has now risen to stand at 50, and that was over the last two weeks.

The CEO says that these figures are encouraging, considering that they are just starting. He projects that by the same time next year, they will have hit the 100-mark in terms of patients.


Aphria Inc (NYSE:APHA) Partly-Owned Australian Subsidiary Althea Gets a Manufacture License from the Australian Authorities

Althea an affiliate of the Aphria Inc (NYSE:APHA) has been cleared by Australian authorities to engage in the manufacture of cannabis-based products in the forms of tinctures and resins. Aphria Inc (NYSE:APHA) broke the news about its Australian strategic partner’s milestone stating that with the much anticipated license, the company can now focus on efforts to make pharmaceutical-grade medical cannabis available to eligible patients in the region.

Entry into manufacturing

Through its CEO Josh Fegan, Althea expressed immense joy in receiving the permit and confirmed that it will now focus on the next step of strategic planning for its cannabis production facility in Victoria. The company’s CEO affirmed that, Althea shareholders can look forward to a vertically integrated, seed-to-sale, state of the art medicinal cannabis operation, comparable to that of our Canadian partner Aphria.”

The manufacture License comes at the time when the company’s medicinal cannabis products are already gaining traction in the market. Patient numbers already under the company’s product’s prescription have surpassed the 100 mark with more and more doctors join the Althea bandwagon even as the company targets over 1,000 patients by this time in 2019. The company’s plans to conduct a series of educations to doctors about the benefits of its products and the effectiveness it brings to ensure that they achieve their goal.

Aphria’s strategic partnership and supply deals

Early this year, Aphria signed a supply agreement with the Australian firm and even investing $2.5 million for 25% equity in the company. The strategic partnership is in line with Aphria’s plan of establishing a global presence for its products and brand.

In regards to the supply agreement, Aphria will be obligated to supply Althea with co-branded cannabis products to for the emerging Australian marijuana market. Althea was already granted the import permit in order to receive the shipments from Canada.

This is not Aphria’s first attempt to enter the Australian Cannabis market. Back in October last year the company shipped its products to Medlab Clinical Limited and it has evidently not gotten enough of the market.


Aphria Inc (OTCMKTS:APHQF) Returns Focus On The Canadian Cannabis Market

Aphria Inc (OTCMKTS:APHQF) will focus more on the Canadian market. The company revealed this in a September 6, 2018 press statement. To that end, the company divested all its assets in the American market. The statement notes that the divestiture comes after due notification process to the staff and investors.

100% divestiture

Further, the statement details that Aphria agreed with “a group of buyers” who will take over the 64 million shares. The company had 100% ownership of Health Sciences, Inc. The subsidiary ran all the Aphria operations in the American cannabis market. However, as part of the terms of the divestiture, Aphria will retain “an irrevocable option to repurchase the Shares or any replacement securities from the buyers for a period of up to five years, subject to the satisfaction of certain conditions.”

Some of the conditions require Aphria to make “a pro rata cash payment” to every single buyer of Liberty shares. Additionally, Aphria will repurchase the shares subject to nationwide legalization of cannabis in the US. Lastly, the repurchase will happen on condition that the Toronto Stock Exchange approves the exercise.

Legal hindrance for Aphria Inc (OTCMKTS:APHQF) to operate optimally

As per Vic Neufeld, CEO of Aphria, the federal legal framework of the US is unfavorable to the medical cannabis business. In fact, company statistics show that it encountered substantial losses in the market. In his words, he says:

“Given the current federal legal framework in the United States, we have made the strategic decision to divest our remaining U.S. holdings at this time in order to permit us to focus on other more immediate capital markets and strategic opportunities in Canada and in other legal markets around the world. Not only does this transaction result in a significant gain to the Company it also enables Aphria to advance its existing global strategic plan unencumbered by U.S. exposure at this time.”

As part of the strategy to establish itself in the new primary market, the company is making strategic partnerships. According to a September 12, 2018 press release, Aphria Inc (OTCMKTS: APHQF) will co-supply medical cannabis products in Canada. The company partnered Emblem Cannabis Corp., which will see them supply 175 tons of cannabis products within five years. As part of the deal, Aphria will take ownership of some of Emblem’s shares.


Aphria Inc (OTCMKTS:APHQF) Plotting A Total Take-over Of The Adult-Use Cannabis Market

A lot seems to be going on for Aphria Inc (OTCMKTS:APHQF) lately as the self-proclaimed global cannabis company has entered several partnerships in a bid to boost its position in the market. In an early August press release, the company announced the signing of a Manufacturer’s Representative agreement with We Grow BC Ltd (“We Grow”) to become the company’s exclusive sales representative in Canada.

Aphria has an extensive portfolio of adult-use brands under its wing and the addition of We Grow is a bold statement by a company that is determined to go the extra mile to be ahead of the competition. The agreement with We Grow adds a second brand of premium B.C.-bud from Boken Coast Cannabis through the company’s coast-to-coast sales distribution network.

We Grow is a licensed producer of premium cannabis based in Vancouver.

In-house adult use brands

Speaking during the announcement, Jakob Ripshtein, Chief Commercial Officer at Aphria, acknowledged the competency of the company to offer a sales and distribution network for adult-use that covers the whole of Canada. In reference to the new partnership with We Grow, the CCO noted that the relationship will be complementary to the company’s existing adult-use brands together with other brands are yet to be made public. The CCO also noted that the partnership with We Grow is an opportunity for the company to expand its portfolio which the company is confident that it will be well represented in stores throughout the country, thanks to well-established relationships and an extensive network of distribution facilities and resources.

Development of new products

In another press release, the company has announced the signing of a Letter of Intent (LOI) to form a joint venture with Perennial Inc. (“Perennial”). The move will see the two companies develop new products that will share in the fortunes of the expanding adult-use cannabis market.

The partnership will be highly reliant on “Aphria’s best-in-class cannabis production” and distribution network while at the same time benefiting from the rich expertise in strategic brand development by Perennial. The collaboration is hoped to develop industry leading products that will put the companies in front of the pack.


Aphria Inc (OTCMKTS:APHQF) Unveils Global Expansion Plans Through Acquisition Of Latin American And Caribbean Assets

Aphria Inc (OTCMKTS:APHQF), a company that deals with the growth of marijuana, has revealed plans to secure its global leadership in the marijuana industry and it involves acquiring key assets in the Caribbean and Latin America.

Aphria has proposed its acquisition of some of the leading companies in the marijuana industry from Jamaica, Argentina, and Colombia. The company plans to spend around $200 million to fulfill the acquisitions.

The assets that Aphria is currently eying in the three countries are either owned or are currently in the process of being acquired by Scythian Biosciences Corp, the sister company to Aphria as well as LATAM Holdings Inc, a subsidiary of Scythian Biosciences (OTCMKTS:SCCYF). Aphria will hand over 15.7 million shares to Scythian in exchange for LATAM Holdings in a deal averaging $12.31 per share which is equivalent to $193 million.

The deal will allow Aphria to own the Colombian firm Colcanna S.A.S. and the latter will, therefore, become the first firm in Colombia’s Coffee Zone to secure a license to produce cannabis extracts for medicinal purposes. It will also have a marijuana research license and a license for extracting and producing cannabis oils for the local market and the export market.

Aphria is planning to acquire a successful Argentine pharmaceutical company called ABP, S.A. that holds numerous licenses including a license for importing CBD oil. ABP is also involved in research pertaining to medical cannabis. Aphria plans to invest in Jamaica through Marigold Projects Jamaica Limited which holds numerous licenses granted by the Jamaican Cannabis Licensing Authority.

Securing an early lead in the increasingly competitive market

The acquisitions should allow Aphria to compete more effectively with other Canadian companies in the rapidly growing marijuana market. It also highlights the aggressive expansion strategies being employed by companies especially after the legalization of marijuana for medical and recreational use in Canada.

Some of the major marijuana companies such as Canopy Growth Corp (NYSE:CGC) have their sight set on Colombia because of its strong agricultural background and the fact that its export channels provide access to the rest of South America. Jamaica also has a positive stance towards marijuana while Argentina allows the importation of CBD products.


Aphria Inc (OTCMKTS:APHQF) Gives A Major Boost To Its Leadership With New Appointments As An Exclusive Agreement Is Struck

The signing of an exclusive supply agreement between Aphria Inc (OTCMKTS:APHQF) and Colcanna SAS is a deal that will help the two businesses come up with better products and services. This announcement was made today by Aphria Inc and it is worth noting that the emerging markets are pulling along with great a promise.

The agreements and everything surrounding it

The CEO of Aphria Vic Neufeld while addressing a number of news reporters said that as a company they were quite pleased to move into the Colombian-market through the exclusive agreement with Colcanna. Aphria, now more than ever is determined on its quest to expand its global leadership through partnerships, investments and agreements such as the one at the moment.

The terms of the agreement provide that Aphria will be the sole supplier of cannabis products to Colcanna. On the other hand, Colcanna is expected to buy medical cannabis products from Aphria and that will be on an exclusive basis.

New appointments

Jakob Ripshtein is the first Chief Commercial Officer of Aphria Inc and that was after the board settled on him as the perfect fit for the position. Christelle Gedeon is the other appointment. Gedeon is with immediate effect taking up the position of the Chief Legal Officer.

The business guru is looking at Jakob as a tremendous addition to its leadership team and it is with great excitement that it welcomes him to be a part of its family. Through its spokesperson, the company has outlined that it won’t stop on its efforts to search for world-class talent and add it in a bid to sharpen its competitive edge in a market characterized by stiff competition.

The CEO of Aphria Vic Neufeld opined, “He brings an incredible track record and a depth of experience in regulated industries that will strengthen our commercial, sales and marketing operations and our entire organization. We’re continuing to add world-class talent as we build Aphria’s bench strength throughout the company.”

Just like the rest of the progressive company’s around the globe, Aphria has had its fair share of challenges. However, it has always taken the right steps to regain its balance.

Pin It on Pinterest